Showing 5241-5250 of 8729 results for "".
- Upadacitinib Linked with Improvement for Hand Eczema in Patients with Atopic Dermatitishttps://practicaldermatology.com/news/updacitinib-shows-promise-for-ad-and-hand-eczema-in-trial/2462198/Results from a new study suggest that upadacitinib is efficacious for the treatment of hand eczema (HE) and atopic dermatitis (AD) in patients with AD. The study authors, publishing in Contact Dermatitis, included a total of 38 patients in the observational cohort analysis (32 of
- Venous Thromboembolism Risk Lower in AD Patients: Analysishttps://practicaldermatology.com/news/venous-thromboembolism-risk-lower-in-ad-patients-analysis/2462196/A retrospective, observational analysis in the Journal of the American Academy of Dermatology showed that patients with atopic dermatitis (AD) do not have an increased risk for venous thromboembolism (VTE) compared with other immune-mediated inflammatory diseases. The ana
- Study: Patient-reported Methods Can Change PSSD Scores, Enhance Interpretationhttps://practicaldermatology.com/news/meaningful-change-thresholds-for-the-psoriasis-symptoms-and-signs-diary/2462195/A new analysis suggests that Psoriasis Symptoms and Signs Diary (PSSD) improvements of 15, 25, or 30 points are indicative of increasing improvements in disease burden useful to patients who have psoriasis. Researchers writing in
- Triple Combo Acne Gel Well-tolerated in Two Studieshttps://practicaldermatology.com/news/triple-combo-acne-gel-well-tolerated-in-phase-2-study/2462194/A triple combination acne gel (IDP-126) was shown to be safe and effective in two phase 3 studies, according to a new analysis. Researchers publishing
- Lower Extremity Lymphedema Linked with Increased Risk for Skin Cancerhttps://practicaldermatology.com/news/lower-extremity-lymphedema-linked-with-increased-risk-for-skin-cancer/2462193/New research suggests that patients with lower extremity lymphedema are at an increased risk for skin cancer. Researchers writing in Mayo Clinic Proceedings enrolled more than 4,400
- PF-07038124 Shows Safety, Efficacy for AD and Plaque Psoriasis: Studyhttps://practicaldermatology.com/news/efficacy-and-safety-of-pf-07038124-in-patients-with-atopic-dermatitis-and-plaque-psoriasis/2462191/A novel topical phosphodiesterase 4 inhibitor (PF-07038124) has been shown to be efficacious and well-tolerated in patients with atopic dermatitis (AD) and plaque psoriasis, according to new study results. Researchers writing in
- Birch Triterpenes Topical Gel Gets FDA Approval for Treatment of Epidermolysis Bullosahttps://practicaldermatology.com/news/birch-triterpenes-topical-gel-gets-fda-approval-for-treatment-of-epidermolysis-bullosa/2462190/Chiesi Global Rare Diseases announced today that the FDA had approved FILSUVEZ® (birch triterpenes) topical gel for the treatment of junctional epidermolysis bullosa (JEB) and dystrophic epidermolysis bullosa (DEB) in patients 6 months or older. According
- Analysis: Vegetarian Diet during Pregnancy Lowers Risk of AD in Childrenhttps://practicaldermatology.com/news/association-between-a-maternal-vegetarian-diet-during-pregnancy-and-the-occurrence-of-atopic-dermatitis-in-children/2462188/A new study published in Pediatric Allergy and Immunology suggested that a vegetarian diet during pregnancy was associated with a reduced risk for atopic dermatitis (AD) in children. Researchers
- Seaweed- and Carbonated Water-based Hydrogel Shows Promise for Treatment of Skin Woundshttps://practicaldermatology.com/news/revolutionary-seaweed-and-carbonated-water-based-hydrogel-for-treating-skin-wounds/2462184/Results from a new study suggested promise for a new seaweed- and carbonated water-based hydrogel that aims to prevent the temporary dilation of wound sites. Researchers developed a low-adhe
- FDA Approves Arcutis’ ZORYVE® (roflumilast) Topical Foam, 0.3% for the Treatment of Seborrheic Dermatitis in Patients 9 Years and Olderhttps://practicaldermatology.com/news/fda-approves-arcutis-zoryve-roflumilast-topical-foam-03-for-the-treatment-of-seborrheic-dermatitis-in-patients-9-years-and-older/2462186/Arcutis Biotherapeutics, Inc. announced the US Food and Drug Administration (FDA) has approved the new drug application (NDA) for ZORYVE (roflumilast) topical foam, 0.3% for the treatment of seborrheic dermatitis in those 9 years of age and older. ZORYVE foam provides rapid disease clearance and